The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.

Can the company add a Car-T string to its stem cell transplant bow?

After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.

Chengdu Kanghong's KH815 enters human testing this month.

A biliary tract cancer trial hits on response rate, but survival data will be key.

Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.

AACR approaches, along with ASCO abstract titles.